SEC Form 10-K filed by HTG Molecular Diagnostics Inc.
$HTGM
Biotechnology: Laboratory Analytical Instruments
Industrials
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/7/2022 | $5.00 → $8.00 | Hold → Buy | Craig-Hallum |
Preliminary full year 2022 unaudited revenue of $6.4 million Cash and cash equivalents of $12.2 million as of December 31, 2022 TUCSON, Ariz., Jan. 06, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today announced certain preliminary, unaudited financial results for the year ended December 31, 2022. Total revenue for the full year 2022 is expected to be approximately $6.4 million, including approximately $2.7 million of HTG Transcriptome Panel (HTP) revenue representing 42% of our total revenue. Cash and cash
TUCSON, Ariz., Aug. 11, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today reported recent business highlights and financial results for the quarter ended June 30, 2022. Throughout the quarter ended June 30, 2022, the Company's technology and strategic development efforts were highlighted in a number of customer and KOL presentations and publications including, but not limited to, the following: A webinar titled "Integration of the HTG Transcriptome Panel into Preclinical and Clinical Programs to Drive Precision Medicine Research" fe
TUCSON, Ariz., Aug. 04, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that it will report its financial results for the quarter ended June 30, 2022 after the market close on Thursday, August 11, 2022. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time. Details for the conference call are as follows: Conference Call & Webcast Details Date:Thursday, August 11Time:4:30pm ETToll Free:1-800-954-0602 International:1-212-231-2936 Conference ID:2
Craig-Hallum upgraded HTG Molecular Diagnostics from Hold to Buy and set a new price target of $8.00 from $5.00 previously
SVB Leerink reiterated coverage of HTG Molecular Diagnostics with a rating of Outperform and set a new price target of $10.00 from $15.00 previously
HC Wainwright & Co. reiterated coverage of HTG Molecular Diagnostics with a rating of Buy and set a new price target of $9.00 from $11.00 previously
8-K - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Filer)
8-K - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Filer)
8-K - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Filer)
TUCSON, Ariz., May 18, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a platform-based life science tools and drug discovery company, today announced that its management team will present the advantages of its proprietary drug discovery engine at the 2023 Biotechnology Innovation Organization (BIO) International Convention and will host in-person meetings during the remaining days of the June 5 – 8, 2023 event in Boston, MA. HTG is pioneering a proprietary platform-based approach that is designed to help improve drug discovery, referred to as transcriptome-informed drug discovery and design. HTG's objective is to develop best-in-class molecules for the treat
TUCSON, Ariz., May 16, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a platform-based life science tools and drug discovery company, today reported achievement of another technical milestone in its drug discovery business. HTG is pioneering a proprietary platform-based approach that is designed to help improve drug discovery, referred to as transcriptome-informed drug discovery and design. HTG's objective is to develop best-in-class molecules for the treatment of diseases, with the ability to apply its platform agnostically across therapy areas. At the center of this approach is HTG's proprietary RNA profiling technologies, functionally married with an adva
TUCSON, Ariz., May 10, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a platform-based life science tools and drug discovery company, today reported financial results for the quarter ended March 31, 2023 and provided recent drug discovery business highlights. HTG has pioneered a proprietary platform-based approach that is designed to help improve drug discovery, referred to as transcriptome-informed drug discovery and design. At the center of this approach is the application of HTG's proprietary RNA profiling technologies, functionally married with advanced medicinal chemistry using a novel artificial intelligence ("AI")-driven platform. This unique drug can
SC 13G/A - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Subject)
SC 13G/A - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Subject)
SC 13G - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Subject)
4 - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Issuer)
4 - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Issuer)
3 - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Issuer)
Gainers Jin Medical International (NASDAQ:ZJYL) stock rose 58.4% to $13.51 during Monday's regular session. The current volume of 4.2 million shares is 8924.5% of Jin Medical International's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $104.7 million. Chinook Therapeutics (NASDAQ:KDNY) stock rose 58.31% to $37.98. Trading volume for this security as of 13:30 EST is 17.3 million, which is 2476.2% of its average full-day volume over the last 100 days. The company's market cap stands at $2.5 billion. Aesthetic Medical Intl (NASDAQ:AIH) stock rose 22.91% to $1.18. Trading volume for Aesthetic Medical Intl's stock is 542.6K as o
Gainers Asset Entities Inc. (NASDAQ:ASST) shares jumped 142% to $2.79 after the company announced the development of an AI bot as part of its AE360DDM suite of services on Discord. Micromobility.com Inc. (NASDAQ:MCOM) shares rose 91.2% to $0.44. Chinook Therapeutics, Inc. (NASDAQ:KDNY) jumped 55.9% to $37.40 after Novartis agreed to acquire the company for $40 per share in cash. Advanced Health Intelligence Ltd. (NASDAQ:AHI) shares gained 44% to $3.14 after jumping 581% on Friday. Auddia Inc. (NASDAQ:AUUD) shares climbed 39.4% to $0.6042. Auddia reported the launch of its faidr 3.0 mobile app. Infobird Co., Ltd (NASDAQ:IFBD) shares climbed 38.8% to $2.02. Infobird recently regaine
Gainers Avalo Therapeutics (NASDAQ:AVTX) shares rose 17.3% to $3.53 during Wednesday's regular session. The company's market cap stands at $46.5 million. Journey Medical (NASDAQ:DERM) shares rose 15.59% to $1.84. Trading volume for this security as of 13:30 EST is 55.9K, which is 228.4% of its average full-day volume over the last 100 days. The company's market cap stands at $33.3 million. Societal CDMO (NASDAQ:SCTL) shares rose 15.14% to $0.9. Trading volume for Societal CDMO's stock is 81.4K as of 13:30 EST. This is 43.5% of its average full-day volume over the last 100 days. The company's market cap stands at $76.2 million. Microbot Medical (NASDAQ:MBOT) stock moved upwards by 14.79%